Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Astrazeneca Plc (AZN)

Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Astrazeneca Plc 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE X0 CB2 0AA GBR

www.astrazeneca.com Employees: 94,300 P: 44-20-3749-5000 F: 122-335-2858

Sector:

Medical

Description:

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Key Statistics

Overview:

Market Capitalization, $K 323,550,432
Enterprise Value, $K 345,658,432
Shares Outstanding, K 1,550,908
Float, K 1,550,908
% Float 100.00%
Short Interest, K 3,881
Short Float 0.25%
Days to Cover 1.00
Short Volume Ratio 0.37
% of Institutional Shareholders 20.35%

Financials:

Annual Sales, $ 58,739 M
Annual Net Income, $ 10,225 M
Last Quarter Sales, $ 15,503 M
Last Quarter Net Income, $ 2,326 M
EBIT, $ 13,743 M
EBITDA, $ 19,476 M

Growth:

1-Year Return 37.25%
3-Year Return 57.16%
5-Year Return 115.61%
5-Year Revenue Growth 120.68%
5-Year Earnings Growth 13.93%
5-Year Dividend Growth 12.04%

Per-Share Information:

Most Recent Earnings 2.12 on 02/10/26
Next Earnings Date 05/05/26
Earnings Per Share ttm 8.10
EPS Growth vs. Prev Qtr -55.46%
EPS Growth vs. Prev Year -49.52%
Annual Dividend & Yield (Paid) 3.07 (1.47%)
Annual Dividend & Yield (Fwd) 2.02 (0.97%)
Most Recent Dividend 2.170 on 02/20/26
Next Ex-Dividends Date 02/20/26
Dividend Payable Date 03/23/15
Dividend Payout Ratio 33.40%
Most Recent Split 1-2 on 02/02/26

AZN Ratios

Ratio
Price/Earnings ttm 25.76
Price/Earnings forward 20.36
Price/Earnings to Growth 1.58
Return-on-Equity % 31.57%
Return-on-Assets % 12.75%
Profit Margin % 17.41%
Debt/Equity 0.57
Price/Sales 5.51
Price/Cash Flow 16.14
Price/Book 6.64
Book Value/Share 31.41
Interest Coverage 8.32
60-Month Beta 0.34

AZN Dividends

Date Value
02/20/26 $2.1700
08/08/25 $0.5050
02/21/25 $1.0300
08/09/24 $0.4900
02/22/24 $0.9650
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar